In a hypertensive, post‑term pregnant patient on methimazole 5 mg once daily with low TSH, low free T4 and normal free T3, what is the diagnosis and how should it be managed?

Diagnosis: Iatrogenic Hypothyroidism (Methimazole Overtreatment)

This patient has developed iatrogenic hypothyroidism from excessive methimazole dosing—immediately reduce the methimazole dose or discontinue it temporarily, as the low TSH with low free T4 indicates overtreatment of her underlying hyperthyroidism, not adequate control.

Clinical Reasoning

The laboratory pattern of low TSH + low free T4 + normal free T3 in a pregnant patient on methimazole is diagnostic of excessive antithyroid drug therapy causing iatrogenic hypothyroidism. This is not the expected pattern of adequately treated hyperthyroidism, which should show suppressed TSH with free T4 at or slightly above the upper limit of normal 1, 2.

Key Diagnostic Points:

• Low free T4 is the critical abnormality—this should never occur during antithyroid drug therapy in pregnancy
• The goal of treatment is to maintain free T4 at or slightly above the upper limit of the nonpregnant reference range, with TSH remaining suppressed 2
• Normal free T3 alone does not indicate adequate thyroid status; free T4 is the primary parameter correlated with good fetal outcome 2

Immediate Management Algorithm

Step 1: Adjust Methimazole Dosing

• Reduce methimazole dose by 50% or discontinue temporarily depending on severity of hypothyroidism
• The current 5 mg daily dose is clearly excessive for this patient's thyroid status
• Do NOT add levothyroxine—block-replacement therapy is contraindicated in pregnancy 2

Step 2: Recheck Thyroid Function

• Repeat thyroid function tests in 2 weeks after dose adjustment 1
• Subsequently monitor every 2-4 weeks until stable 1, 2
• Target: Free T4 at or slightly above upper limit of normal range with suppressed TSH

Step 3: Address Post-Term Pregnancy Status

This patient is post-term and hypertensive—obstetric management takes priority:

• Coordinate with obstetrics for delivery planning
• Post-delivery, most hypothyroid women need to decrease T4 dosage to prepregnancy levels 1
• However, this patient is currently overtreated with methimazole, not undertreated with levothyroxine

Critical Medication Considerations for Post-Term Pregnancy

Since this patient is post-term (beyond first trimester), methimazole is the appropriate antithyroid drug 2. The guidelines clearly state:

• Propylthiouracil should be used in first trimester only due to methimazole teratogenicity risk 2, 3
• Switch to methimazole after first trimester due to PTU hepatotoxicity risk 1, 2
• This patient is already on the correct drug for her gestational age

Common Pitfalls to Avoid

1. Do not add levothyroxine thinking this is primary hypothyroidism—this is drug-induced and requires dose reduction, not supplementation
2. Do not continue current methimazole dose hoping TSH will normalize—the low free T4 indicates fetal thyroid suppression risk
3. Do not ignore the hypertension—coordinate thyroid and obstetric management, as uncontrolled hyperthyroidism can worsen hypertension, but this patient is currently overtreated
4. Do not use total T4 alone—free T4 estimates are essential for proper monitoring 2

Monitoring Strategy

Monthly thyroid function assessment is mandatory once stable 2:

• Free T4 should be kept at or slightly above upper limit of nonpregnant reference range
• TSH will remain suppressed during active Graves' disease treatment
• Adjust antithyroid drug dose based primarily on free T4, not TSH 2

Post-Delivery Considerations

After delivery, this patient will likely need:

• Further reduction or discontinuation of methimazole if she was in remission
• Close monitoring for postpartum thyroid dysfunction relapse (common in Graves' disease) 2
• If breastfeeding, methimazole is safe at low doses and preferred over PTU 2, 3

The hypertension requires separate evaluation for preeclampsia versus chronic hypertension, but the thyroid overtreatment should be corrected immediately as it provides no benefit and poses fetal risk.